Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Down Today?
By the Top Tier Newswire AI Desk · October 22, 2026 at 12:02 AM ET · reviewed against 17 wire stories
RAPPORT THERAPEUTICS Equity (RAPP) is down -14.67% in the latest session. Our newswire has captured 17 stories on RAPP across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 62/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Rapport Therapeutics shares fell 14.67% to close at $25.06. The decline followed the company’s announcement of positive Phase 2 topline results for RAP-219 in acute bipolar mania. Despite the successful trial data, the stock moved lower as analysts adjusted their valuations and the stock printed new 52-week lows.
What Happened
Rapport Therapeutics reported that RAP-219 met its primary and secondary endpoints in a Phase 2 trial for acute bipolar mania. The data showed a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale at Week 3, with a p-value of 0.045. The company stated these results set up discussions with the FDA and a path toward Phase 3 trials.
Analyst reactions were mixed following the data release. Guggenheim raised its price target to $70 from $65. Jones Trading raised its target to $82 from $50. Conversely, Wells Fargo lowered its price target to $50 from $51, citing first-order risk. Raymond James increased its target to $86, while HC Wainwright & Co. maintained its Buy rating with a $66 target. The stock has been under pressure recently, moving down 16.1% over the last eight sessions from $30.15 to $25.29.
What The Data Shows
The stock printed 24 fresh 52-week lows on October 21, 2026. The 52-week range stands at $23.75 to $52.93. Rapport Therapeutics has a market capitalization of $1.4 billion and is unprofitable, with trailing twelve-month earnings per share of negative $3.05. The stock has a beta of 1.22.
Insider activity shows a net selling trend over the last 90 days. There were nine sells totaling $7.0 million and one buy totaling $144,000. CFO Troy A. Ignelzi bought shares on October 21, 2026. CEO Abraham Ceesay sold shares on October 6, 2026, and COO Cheryl Gault sold shares on September 30, 2026.
What To Watch
Coverage of the stock has increased, with 17 stories from 8 sources in the last 36 hours. Investors will monitor the company’s next steps in FDA discussions and the initiation of Phase 3 trials for RAP-219.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 17 stories · 62/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
19h agoMarketChameleonBULLISH 74Product/PR
Rapport’s RAP-219 posts statistically significant Phase 2 bipolar mania wins, setting up FDA talks and a Phase 3 path
October 21, 2026
Rapport Therapeutics reported positive Phase 2 topline results for RAP-219 in acute bipolar mania, meeting primary and secondary endpoints with a 3.1-point placebo-adjusted improvement in YMRS at Week 3 (p=0.045) and a 0.4-point improvement in CGI-BP mania severity (p=0.024). The company said the drug was well tolerated with no serious adverse events during treatment, and it expects FDA discussions in Q1 2027 ahead of planned Phase 3 trial starts in the second half of 2027.
22h agoThe FlyBULLISH 64Analyst
Rapport Therapeutics price target raised to $70 from $65 at Guggenheim
Wells Fargo cuts Rapport Therapeutics price target on FOS risk
Wells Fargo cuts Rapport Therapeutics price target on FOS risk
1d agoSeeking AlphaBULLISH 58Product/PR
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update October 20, 2026 8:00 AM EDTCompany ParticipantsJulie...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →